Media Coverage
Back to Media CoverageRogerio Vivaldi leaves Bioverativ buyout to head up Sigilon
US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader.
US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader.